PHR

PhreesiaC

NYSE / Health Care Equipment & Services

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$14.00

Analysis reference price unavailable

Analysis 2026-09-24 · RankAlpha Sentiment Codex

Most likely

Base case

50%

Probability

Target price

$11.00

Analysis reference price unavailable

Analysis 2026-09-24 · RankAlpha Sentiment Codex

B-

Bear case

25%

Probability

Target price

$7.00

Analysis reference price unavailable

Analysis 2026-09-24 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-09-24

AI commentary

Company-source tone is cautiously constructive, but Q2 was described as in line with expectations and guidance was maintained, not raised. An attributable post-release price reaction, earnings surprise versus consensus, and verified analyst revisions were unavailable. The zero sentiment fields denote unavailable measurements, not neutral readings; social coverage was not supplied.

RankAlpha Sentiment Codex - 2026-09-24

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-12-31eventFiscal 2027 outlook tests network-solutions visibilityHigh impact

Phreesia maintained fiscal 2027 revenue guidance of $510 million–$520 million and adjusted EBITDA guidance of $125 million–$135 million. Management flagged greater variability in network-solutions revenue forecasting, especially in the fiscal second half. The next results update could clarify whether that risk is contained; its date is not confirmed here. [#8-K-2026-09-02] [#SEC-8K-2026-09-02]

2026-12-31catalystQ2 cash flow and profitability support the thesisMedium impact

Fiscal Q2 revenue rose 10% year over year to $129.5 million, adjusted EBITDA reached $32.9 million, and free cash flow was $13.8 million. Continued cash generation could support the shares, though management characterized the quarter as in line with expectations rather than an upside surprise. [#8-K-2026-09-02] [#SEC-8K-2026-09-02]

2027-07-31catalystAccessOne and ProviderConnect commercializationHigh impact

Management identified AccessOne and ProviderConnect as potential growth drivers. Fiscal 2027 revenue guidance assumes approximately $37 million from AccessOne, but the available evidence does not quantify ProviderConnect adoption or incremental revenue. Demonstrated contribution beyond current assumptions would strengthen the longer-term case. [#8-K-2026-09-02] [#SEC-8K-2026-09-02]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-09-24 • Updated nightlySource: Internal modelMethodology